ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients

H. Wadei,1 H. Saull,2 C. Enderby,2 M. Mai,1 M. Prendergast,1 T. Gonwa.1

1Transplant, Mayo Clinic, Jacksonville, FL
2Pharmacy, Mayo Clinic, Jacksonville, FL.

Meeting: 2015 American Transplant Congress

Abstract number: 426

Keywords: Induction therapy, Kidney transplantation, Polyma virus

Session Information

Session Name: Concurrent Session: BK Virus Infection After Kidney Transplantation

Session Type: Concurrent Session

Date: Tuesday, May 5, 2015

Session Time: 4:00pm-5:30pm

 Presentation Time: 4:00pm-4:12pm

Location: Room 115-C

Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients who received either rabbit anti-thymocyte globulin (rATG) (n=100) or almetuzumab (n=100). All patients received 5 days of corticosteroids, tacrolimus (target 8-10 ng/ml 1st month then 6-8 ng/ml) and mycophenolate mofetil (MMF) at 2 gr/d. Patients with PRA >20% were excluded. Plasma BK PCR and protocol biopsies were obtained at 1,4 and 12 months post-tx. PVAN was treated with immunosuppression (IS) reduction. Results: Patients' and transplant characteristics are presented in Table 1

Table 1: Baseline characteristics
  rATG (n=100) Alemtuzumab (n=100) P
Age (yr) 56±13 52.8 ± 13.6 0.1
% Male 53 57 0.6
% Caucasian 51 57 0.2
% Living donor 41 31 0.1
% Pre-emptive tx 24 24 1
% DCD 10 18 0.1
% DGF 8 16 0.08
% ≥3 HLA match 34 27 0.5
Cold ischemia time (hr) 10±8 11±7 0.1
Warm ischemia time (min) 37±13 39±12 0.3
DCD: donation after cadiac death; DGF: delayed graft functionAt 1- year, 34 and 28 patients developed BK viremia in the almetuzumab and rATG groups, respectively (P=0.3) but PVAN was more common in the alemtuzumab (P=0.01) (Figure 1) Acute cellular rejection (ACR) Banff IA or higher was more common in the alemtuzumab group (P=0.005) (figure 2) and was preceded by PVAN preceded in 11/19 (58%) of cases.At time of ACR, trough tacrolimus (6±2 vs 9±5 ng/ml, P=0.005) and daily MMF dose (1.2±0.6 vs 1.7±0.5, P=0.007) were lower in the almetuzumab group.Conclusions:1)Despite similar rates of BK viremia, alemtuzumab was associated with higher risk of PVAN on protocol biopsies.2)IS reduction following PVAN diagnosis contributed to higher rates of ACR in the almetuzumab group

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Wadei H, Saull H, Enderby C, Mai M, Prendergast M, Gonwa T. Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/alemtuzumab-induction-is-associated-with-higher-risk-of-polyomavirrus-associated-nephropathy-pvan-in-kidney-transplant-recipients/. Accessed June 5, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences